NCT02568306View on ClinicalTrials.gov

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

October 5, 2015

Primary Completion Date

February 7, 2017

Study Completion Date

February 7, 2017

Conditions
Metabolism and Nutrition DisorderObesity
Interventions
DRUG

NNC0165-1562

Administered subcutaneously (s.c., under the skin) single dose \[SD\] or multiple dose \[MD\] with daily dosing.

DRUG

placebo

Administered subcutaneously (s.c., under the skin) single dose \[SD\]) or multiple dose \[MD\] with daily dosing.

Trial Locations (1)

85283

Novo Nordisk Investigational Site, Tempe

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY